BridgeMD
New treatment option for XIAP Deficiency
Official title Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency
ClinicalTrials.gov ID: NCT07433621
What this study is testing
What is Quercetin?
Quercetin is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for xiap deficiency.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a naturally occurring antioxidant that has many properties including the ability to decrease inflammation in other diseases.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 2 and older, men only
You may be able to join if
- Male patients
- Diagnosis of XIAP deficiency
- Patients ≥2 years of age
- Serum IL-18 ≥600 pg/mL (approximately 25% above the lab-defined upper limit of normal of 477 pg/mL)
- Able to take enteral medication
You likely can't join if
- Renal failure requiring dialysis
- Total bilirubin \>3 mg/dl and/or SGPT \>300 at time of enrollment
- Patients receiving digoxin therapy, who are unable to discontinue treatment due to medical reasons
- Patients receiving fluoroquinolone therapy, who are unable to discontinue treatment due to medical reasons
- Patients who are at risk of pregnancy or fathering a child and are unable to use acceptable methods of birth control during the length of the study
- Patients who have received quercetin or any over the counter anti-oxidant supplementation within last 1 month
See the full eligibility criteria
- Male patients
- Diagnosis of XIAP deficiency
- Patients ≥2 years of age
- Serum IL-18 ≥600 pg/mL (approximately 25% above the lab-defined upper limit of normal of 477 pg/mL)
- Able to take enteral medication
- Renal failure requiring dialysis
- Total bilirubin \>3 mg/dl and/or SGPT \>300 at time of enrollment
- Patients receiving digoxin therapy, who are unable to discontinue treatment due to medical reasons
- Patients receiving fluoroquinolone therapy, who are unable to discontinue treatment due to medical reasons
- Patients who are at risk of pregnancy or fathering a child and are unable to use acceptable methods of birth control during the length of the study
- Patients who have received quercetin or any over the counter anti-oxidant supplementation within last 1 month
- Patients with unstable disease status or other medical issues requiring hospitalization or rapid escalation of medical care
- Participating in another therapeutic study for XIAP deficiency
The study team makes the final eligibility decision.
Where it's taking place
- Cincinnati, Ohio, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 2 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cincinnati, Ohio, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.